Analysts expect Monte Rosa Therapeutics, Inc. to report revenue of 31.80 M for Q3 26, against a range of 30.11 M to 33.48 M. The most recent reported quarter, Q2 26, came in at 9.00 M, a 27.8% miss against the 12.47 M consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 9.20 M | 60.60 M | 84.93 M | 23.19 M | 12.80 M | 2.80 M | 4.20 M | 9.00 M | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | 2.88 M | 46.45 M | 42.47 M | 7.37 M | 8.38 M | 18.13 M | 12.08 M | 12.97 M | 33.48 M | 23.79 M | 4.45 M | 3.94 M | 26.45 M | 24.30 M | 23.39 M | 18.30 M | ||||||||||
| Low Estimate | 2.57 M | 43.64 M | 35.71 M | 6.88 M | 7.19 M | 14.88 M | 10.73 M | 11.97 M | 30.11 M | 20.31 M | 3.70 M | 3.54 M | 24.61 M | 21.78 M | 20.62 M | 15.37 M | ||||||||||
| Consensus Estimate | 2.73 M | 45.04 M | 39.09 M | 7.13 M | 7.79 M | 16.50 M | 11.40 M | 12.47 M | 31.80 M | 22.05 M | 4.08 M | 3.74 M | 25.53 M | 23.04 M | 22.00 M | 16.84 M |
Analysts expect Monte Rosa Therapeutics, Inc. to report earnings per share of -0.25 for Q3 26, against a range of -0.27 to -0.23. The most recent reported quarter, Q2 26, came in at -0.43, a 19.4% miss against the -0.36 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.29 | 0.16 | 0.57 | -0.15 | -0.33 | -0.54 | -0.45 | -0.43 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | -0.47 | 0.02 | 0.00 | -0.33 | -0.34 | -0.34 | -0.35 | -0.34 | -0.23 | -0.37 | -0.57 | -0.55 | -0.41 | -0.47 | -0.40 | -0.52 | ||||||||||
| Low Estimate | -0.53 | 0.02 | 0.00 | -0.37 | -0.38 | -0.40 | -0.41 | -0.38 | -0.27 | -0.41 | -0.65 | -0.65 | -0.49 | -0.53 | -0.44 | -0.56 | ||||||||||
| Consensus Estimate | -0.50 | 0.02 | 0.00 | -0.35 | -0.36 | -0.37 | -0.38 | -0.36 | -0.25 | -0.39 | -0.61 | -0.60 | -0.45 | -0.50 | -0.42 | -0.54 |
Pull Wall Street consensus for Monte Rosa Therapeutics, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=GLUE&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "GLUE", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=GLUE&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();